1. Alberts AR, Schoots IG, Roobol MJ. Prostate-specific antigen-based prostate cancer screening: past and future. Int J Urol. 2015;22(6):524-532. doi:10.1111/iju.12750
2. Turkbey B,Mani H,Shah V,et al.Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol. 2011;186(5):1818-1824. doi:10.1016/j.juro. 2011.07.013
3. Habchi H,Bratan F,Paye A,et al.Value of prostate multiparametric magnetic resonance imaging for predicting biopsy results in first or repeat biopsy.Clin Radiol.2014;69(3):e120-e128.
4. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815-822. doi:10.1016/S0140-6736(16)32401-1
5. Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol. 2011; 59(4):477-494. doi:10.1016/j.eururo.2010.12.009
6. Weinreb JC, Barentsz JO, Choyke PL, et al. PI-rads prostate imaging-reporting and data system: 2015, version 2. Eur Urol. 2016;69(1):16-40. doi: 10.1016/j.eururo.2016.04.016
7. Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390-397. doi:10.1001/jama.2014.17942
8. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815-822. doi:10.1016/S0140-6736(16)32401-1
9. Rouvière O, Puech P, Renard-Penna R, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRIFIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2019;20(1):100-109. doi:10.1016/S1470-2045(18)30569-2
10. Kasivisvanathan V, Emberton M, Moore CM. MRI-targeted biopsy for prostate cancer diagnosis. N Engl J Med. 2018;379(6):589-590. doi:10.1056/NEJMc1807507
11. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767-1777. doi:10.1056/NEJMoa1801993
12. Dros FH, Osses D, Nieboer D, et all.<strong> </strong>Prostate magnetic resonance imaging, with or without magnetic<strong> </strong>resonance imaging-targeted biopsy, and systematic biopsy for<strong> </strong>detecting prostate cancer: a cochrane systematic review and<strong> </strong>meta-analysis. Eur Urol. 2020;77(1):78-94. doi:10.1016/j.eururo.2019.06.023
13. Moore CM, Kasivisvanathan V, Eggener S, et al. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol. 2013;64(4):544-552. doi: 10.1016/j.eururo.2013.03.030
14. Rhudd A, McDonald J, Emberton M, Kasivisvanathan V. The role of the multiparametric MRI in the diagnosis of prostate cancer in biopsy-naive men. Curr Opin Urol. 2017;27(5):488-494. doi:10.1097/MOU. 0000000000000415
15. Panebianco V, Barchetti F, Sciarra A, et al. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study.Urol Oncol.2015; 33(1):17.e1-17.e7.
16. Hoeks CM, Schouten MG, Bomers JG, et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.Eur Urol.2012;62(5):902-909.
17. Sonn GA, Chang E, Natarajan S, et al. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen.Eur Urol.2014;65(4):809-815.